Additionally, a novel NUP98-NSD1 siRNA-LNP formulation was validated as an effective treatment strategy for NUP98-NSD1-positive AML, supporting the preclinical and clinical development of this treatment approach to improve the outcome of NUP98-NSD1-positive AML patients. Here, NUP98 is linked to acute myeloid leukemia.